A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2021

Primary Completion Date

November 30, 2026

Study Completion Date

December 31, 2026

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG

BEY1107

Administer once daily, PO, 3-week continuous dose.

COMBINATION_PRODUCT

Capecitabine

Administer twice daily, PO, 2-week continuous dose, followed by 1-week rest period.

Trial Locations (1)

RECRUITING

Seoul National University Hospial, Seoul

All Listed Sponsors

lead

BeyondBio Inc.

INDUSTRY